All In Biotech

Drug Trial Radar · NCT06044337

A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

A Multicenter, Open-Label, Single-Arm, Phase 3, Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of BIIB059 (Litifilimab) in Adult Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy

Last checked: Nov 19, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

306

Planned (sponsor's estimate)

Start

Oct 3, 2023

Primary completion

Jun 26, 2029

Study completion Dec 11, 2029

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Sep 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, researchers will learn more about a study drug called BIIB059 (litifilimab) in participants with cutaneous lupus erythematosus (CLE). The study will focus on participants who have either active subacute CLE or chronic CLE, or both. They may also have systemic lupus erythematosus (SLE). The participants did not respond to antimalarial therapy or had problems with the treatment that made it hard to continue. The study will enroll only those participants who have completed treatment with litifilimab in the parent study, 230LE301. The main objective of the study is to learn more about the long-term safety of litifilimab. The main question researchers want to answer is: * How many participants have adverse events and serious adverse events after taking litifilimab? Adverse events are health problems that may or may not be caused by the study drug. Researchers will also learn more about the effect of litifilimab on CLE. They will do this by measuring the symptoms of CLE over time using a variety of scoring tools. These include the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI), the Cutaneous Lupus Activity of Investigator's Global Assessment-Revised (CLA-IGA-R), and the SELENA-SLEDAI Flare Index (SFI). Researchers will look at how litifilimab and CLE affect the quality of life of participants using a group of questionnaires. They will also look at how litifilimab affects laboratory tests and how participants' immune systems respond to litifilimab. The study will be done as follows: * The last visit of parent study 230LE301 will be the first visit of study 230LE305. * All participants will receive litifilimab as an injection under the skin once every 4 weeks. Both researchers and participants will know the dose and identity of the study drug. * Globally, the treatment period will last up to 208 weeks, or 4 years. Participants will have up to 53 study visits during this time.

Conditions

  • Subacute Cutaneous Lupus Erythematosus
  • Chronic Cutaneous Lupus Erythematosus

Interventions

  • BIIB059 (litifilimab)Drug

    Administered as specified in the treatment arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: Up to 232 weeks

Locations

104 sites in 25 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham - (UAB)

    Birmingham, Alabama

  • Arizona Arthritis & Rheumatology Research, PLLC

    Phoenix, Arizona

  • Dermatology Research Associates

    Los Angeles, California

  • Inland Rheumatology Clinical Trials, Inc.

    Upland, California

  • David Fivenson, MD, Dermatology, PLLC

    Ann Arbor, Michigan

  • Revival Research Institute, LLC

    Troy, Michigan

  • Saint Louis University

    St Louis, Missouri

  • Thurston Arthritis Research Center

    Chapel Hill, North Carolina

  • Duke Dermatology South Durham

    Durham, North Carolina

  • University of Cincinnati Health Physicians Office Dermatology

    Cincinnati, Ohio

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • UT Southwestern Medical Center

    Dallas, Texas

  • Precision Comprehensive Clinical Research Solutions

    Grapevine, Texas

  • APRILLUS Asistencia e Investigacion

    Buenos Aires, Argentina

  • Instituto CAICI

    Rosario, Santa Fe Province, Argentina

  • Investigaciones Clinicas Tucuman

    San Miguel de Tucumán, Tucumán Province, Argentina

  • Centro de Investigaciones Medicas Tucuman

    San Miguel de Tucumán, Tucumán Province, Argentina

  • IDERJ - Instituto de Dermatologia e Estética do Brasil Ltda

    Rio de Janeiro, Brazil

  • Clínica SER da Bahia

    Salvador, Estado de Bahia, Brazil

  • L2IP - Instituto de Pesquisas Clínicas Ltda.

    Brasília, Federal District, Brazil

  • IPC MT Instituto de Pesquisas Clinicas do Mato Grosso

    Santo Ângelo, Mato Grosso, Brazil

  • CMiP - Centro Mineiro de Pesquisa

    Juiz de Fora, Minas Gerais, Brazil

  • Hospital de Clínicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

  • Nucleo de Pesquisa Clinica do Rio Grande do Sul

    Porto Alegre, Rio Grande do Sul, Brazil

  • LMK Serviços Médicos S/S Ltda

    Porto Alegre, Rio Grande do Sul, Brazil

  • CEPIC - Centro Paulista de Investigação Clínica e Serviços Médicos

    São Paulo, São Paulo, Brazil

  • DCC 'Alexandrovska', EOOD

    Sofia, Bulgaria

  • DCC Focus 5 - MEOH OOD

    Sofia, Bulgaria

  • University Multiprofile Hospital for Active Treatment Sv Ivan Rilski EAD

    Sofia, Sofia City Province, Bulgaria

  • Laser Rejuvenation Clinics, Inc.

    Calgary, Alberta, Canada

  • DIEX Recherche Sherbrooke Inc.

    Sherbrooke, Quebec, Canada

  • Centro Medico SkinMed

    Las Condes, Chile

  • CIEC - Centro Internacional de Estudios Clínicos

    Santiago, Chile

  • Clinical Research Chile SpA

    Valdivia, Chile

  • Beijing Tongren Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Shenzhen Second People's Hospital

    Shenzhen, Guangdong, China

  • Dongguan People's Hospital

    Dongguan, Guangdongsheng, China

  • Nanfang Hospital of Southern Medical University

    Guangzhou, Guangdongsheng, China

  • The second Xiangya Hospital of Central South University

    Changsha, Húnánsheng, China

  • Hospital for Skin Diseases, Chinese Academy of Medical Sciences

    Nanjing, Jiangsu, China

Showing 40 of 104 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.